JP2013525472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525472A5 JP2013525472A5 JP2013508516A JP2013508516A JP2013525472A5 JP 2013525472 A5 JP2013525472 A5 JP 2013525472A5 JP 2013508516 A JP2013508516 A JP 2013508516A JP 2013508516 A JP2013508516 A JP 2013508516A JP 2013525472 A5 JP2013525472 A5 JP 2013525472A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- hydrogen
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 59
- 239000001257 hydrogen Substances 0.000 claims 59
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- -1 4-methyl-1-imidazolyl Chemical group 0.000 claims 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 1
- LYERDLOJXZZCLH-UHFFFAOYSA-N 3-(2-imidazol-1-yl-1,3-benzoxazol-6-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3C=NC=C3)C2=C1 LYERDLOJXZZCLH-UHFFFAOYSA-N 0.000 claims 1
- XOJQFYDKGRNAGE-UHFFFAOYSA-N 3-(2-piperazin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)N2CCNCC2)=N1 XOJQFYDKGRNAGE-UHFFFAOYSA-N 0.000 claims 1
- JJDHQIXXASOFEU-UHFFFAOYSA-N 3-(2-pyridin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C=2N=CC=CC=2)=N1 JJDHQIXXASOFEU-UHFFFAOYSA-N 0.000 claims 1
- NUENUAKRFGZENA-UHFFFAOYSA-N 3-(2-pyrrolidin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)N2CCCC2)=N1 NUENUAKRFGZENA-UHFFFAOYSA-N 0.000 claims 1
- VJRBSHZAWWZIKM-UHFFFAOYSA-N 3-(2-thiophen-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C2=CSC=C2)=N1 VJRBSHZAWWZIKM-UHFFFAOYSA-N 0.000 claims 1
- DPWPMUSGLLXNQL-UHFFFAOYSA-N 3-[2-(2,6-dichloropyridin-3-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C(=NC(Cl)=CC=3)Cl)C2=C1 DPWPMUSGLLXNQL-UHFFFAOYSA-N 0.000 claims 1
- JPXHMLGSNZNILO-UHFFFAOYSA-N 3-[2-(2-chloro-6-morpholin-4-ylpyridin-3-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C(=NC(=CC=3)N3CCOCC3)Cl)C2=C1 JPXHMLGSNZNILO-UHFFFAOYSA-N 0.000 claims 1
- ONQJAHPGSXJCAC-UHFFFAOYSA-N 3-[2-(4-methylpiperazin-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1CN(C)CCN1C1=NC2=CC=C(C=3CCC(=O)NN=3)C=C2O1 ONQJAHPGSXJCAC-UHFFFAOYSA-N 0.000 claims 1
- ZAUCTQWJCVGYJO-UHFFFAOYSA-N 3-[2-(6-aminopyridin-3-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC(N)=CC=3)C2=C1 ZAUCTQWJCVGYJO-UHFFFAOYSA-N 0.000 claims 1
- KXAXSCKODDCDEI-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=C3OC(=NC3=CC=2)C=2OC=CC=2)=N1 KXAXSCKODDCDEI-UHFFFAOYSA-N 0.000 claims 1
- ONMHFWXBCYQUHR-UHFFFAOYSA-N 3-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3OC=CC=3)C2=C1 ONMHFWXBCYQUHR-UHFFFAOYSA-N 0.000 claims 1
- RZFBQWBFPTUWJO-UHFFFAOYSA-N 4-methyl-3-(2-piperazin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3CCNCC3)C2=C1 RZFBQWBFPTUWJO-UHFFFAOYSA-N 0.000 claims 1
- PEYREFTTXSMFJA-UHFFFAOYSA-N 4-methyl-3-(2-pyrazin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3N=CC=NC=3)C2=C1 PEYREFTTXSMFJA-UHFFFAOYSA-N 0.000 claims 1
- WBLUKZKWOCUDNJ-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3N=CC=CC=3)C2=C1 WBLUKZKWOCUDNJ-UHFFFAOYSA-N 0.000 claims 1
- HZPCPJCKBVVBPN-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC=CC=3)C2=C1 HZPCPJCKBVVBPN-UHFFFAOYSA-N 0.000 claims 1
- GVFKMZWXGLRDSL-UHFFFAOYSA-N 4-methyl-3-(2-pyridin-4-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=CN=CC=3)C2=C1 GVFKMZWXGLRDSL-UHFFFAOYSA-N 0.000 claims 1
- GWVGQEHDTMTWGA-UHFFFAOYSA-N 4-methyl-3-(2-pyrimidin-5-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC=NC=3)C2=C1 GWVGQEHDTMTWGA-UHFFFAOYSA-N 0.000 claims 1
- OJQZGKVBHOCFJU-UHFFFAOYSA-N 4-methyl-3-(2-pyrrolidin-1-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3CCCC3)C2=C1 OJQZGKVBHOCFJU-UHFFFAOYSA-N 0.000 claims 1
- UZUZMMPWZNVNSQ-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-2-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3SC=CC=3)C2=C1 UZUZMMPWZNVNSQ-UHFFFAOYSA-N 0.000 claims 1
- AWBKPTGTOZQNBX-UHFFFAOYSA-N 4-methyl-3-(2-thiophen-3-yl-1,3-benzoxazol-6-yl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C3=CSC=C3)C2=C1 AWBKPTGTOZQNBX-UHFFFAOYSA-N 0.000 claims 1
- CZPRHQWMFUDXEY-UHFFFAOYSA-N 4-methyl-3-[2-(4-methyl-1,3-oxazol-5-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C3=C(N=CO3)C)C2=C1 CZPRHQWMFUDXEY-UHFFFAOYSA-N 0.000 claims 1
- FLXOYHPHHSLXTD-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylimidazol-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3C=C(C)N=C3)C2=C1 FLXOYHPHHSLXTD-UHFFFAOYSA-N 0.000 claims 1
- JXRPBDVBPMFUDP-UHFFFAOYSA-N 4-methyl-3-[2-(4-methylpiperazin-1-yl)-1,3-benzoxazol-6-yl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)N3CCN(C)CC3)C2=C1 JXRPBDVBPMFUDP-UHFFFAOYSA-N 0.000 claims 1
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 229940100607 GPR119 agonist Drugs 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- GYNWJIUVGYDGQS-UHFFFAOYSA-N ethyl 4-[6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2O1 GYNWJIUVGYDGQS-UHFFFAOYSA-N 0.000 claims 1
- DROVXVPSOQWXQP-UHFFFAOYSA-N ethyl 4-[6-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=NC2=CC=C(C=3CCC(=O)NN=3)C=C2O1 DROVXVPSOQWXQP-UHFFFAOYSA-N 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- LTUZASMLIZCACN-UHFFFAOYSA-N n-[5-[6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,3-benzoxazol-2-yl]pyridin-2-yl]acetamide Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(O2)C=3C=NC(NC(C)=O)=CC=3)C2=C1 LTUZASMLIZCACN-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162364 | 2010-05-07 | ||
| EP10162364.3 | 2010-05-07 | ||
| PCT/EP2011/057285 WO2011138427A2 (en) | 2010-05-07 | 2011-05-06 | Pyridazinones as gpr119 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525472A JP2013525472A (ja) | 2013-06-20 |
| JP2013525472A5 true JP2013525472A5 (https=) | 2014-06-26 |
| JP5794297B2 JP5794297B2 (ja) | 2015-10-14 |
Family
ID=42711866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508516A Active JP5794297B2 (ja) | 2010-05-07 | 2011-05-06 | Ｇｐｒ１１９アゴニストとしてのピリダジノン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8772323B2 (https=) |
| EP (1) | EP2566864B1 (https=) |
| JP (1) | JP5794297B2 (https=) |
| WO (1) | WO2011138427A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201200046A1 (ru) | 2009-06-24 | 2012-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые соединения, фармацевтическая композиция и связанные с ними способы |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| EP2566864B1 (en) * | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| US8778926B2 (en) | 2011-01-21 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| KR101913619B1 (ko) * | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| US8921398B2 (en) | 2011-06-09 | 2014-12-30 | Boehringer Ingelheim International Gmbh | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof |
| JP6119088B2 (ja) * | 2012-06-12 | 2017-04-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン−２−イル−ピペリジン誘導体、それらを含む医薬組成物及びその使用 |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| US20170216252A1 (en) * | 2014-07-11 | 2017-08-03 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
| EA201890086A1 (ru) | 2015-06-18 | 2018-06-29 | Сефалон, Инк. | 1,4-замещенные производные пиперидина |
| EP3436457B1 (en) | 2016-04-01 | 2022-07-20 | Basf Se | Bicyclic compounds |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| CN107857720A (zh) * | 2017-10-26 | 2018-03-30 | 中山大学 | 一种西洛多辛手性中间体的制备方法 |
| JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ） |
| WO2020157194A1 (en) | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3511110A1 (de) | 1985-03-27 | 1986-10-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| WO2007003961A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JP2008063265A (ja) * | 2006-09-06 | 2008-03-21 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| EP2058308A1 (fr) | 2007-11-12 | 2009-05-13 | Merck Sante | Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant. |
| US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| EP2566864B1 (en) * | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
-
2011
- 2011-05-06 EP EP11718989.4A patent/EP2566864B1/en active Active
- 2011-05-06 WO PCT/EP2011/057285 patent/WO2011138427A2/en not_active Ceased
- 2011-05-06 US US13/696,094 patent/US8772323B2/en active Active
- 2011-05-06 JP JP2013508516A patent/JP5794297B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525472A5 (https=) | ||
| AU2020257055B2 (en) | Cot modulators and methods of use thereof | |
| JP7579789B2 (ja) | 免疫調節剤、組成物およびその使用方法 | |
| JP6462911B2 (ja) | ６−（５−ヒドロキシ−１ｈ−ピラゾール−１−イル）ニコチンアミド誘導体およびｐｈｄ阻害剤としてのそれらの使用 | |
| CA2858647C (en) | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b. | |
| AU2015236428B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| AU2011322562B2 (en) | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or Alzheimer's disease | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| EP2794597A1 (en) | Pyridinone and pyrimidinone derivatives as factor xia inhibitors | |
| JP2019512485A (ja) | オルトミクソウイルス感染の処置に有用な三環式化合物 | |
| EP2909193A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| KR20130062951A (ko) | 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물 | |
| CA2714058A1 (en) | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2011029027A1 (en) | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | |
| TW201109323A (en) | Heterocyclic compounds | |
| AU2024322339A1 (en) | 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof | |
| WO2015057205A1 (en) | Methylene linked quinolinyl modulators of ror-gamma-t | |
| AU2023317959A1 (en) | Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | |
| CN106414406A (zh) | 环己基吡啶衍生物 | |
| JPWO2014069554A1 (ja) | キヌクリジンアミド誘導体及びその医薬用途 | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| AU2016378154B2 (en) | Phenylimidazole compound | |
| WO2008157210A1 (en) | Compounds and compositions as itpkb inhibitors | |
| EP3057950A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| WO2024011116A2 (en) | Potent and selective irreversible inhibitors of irak1 |